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Reviews of the efﬁcacy of acupuncture as a treatment for acute low back pain (aLBP) have shown that
there is insufﬁcient evidence for its effect and that more research is needed. Motion style acupuncture
treatment (MSAT) is novel in that it requires a part of the patient’s body to move passively or actively
while acupuncture needles are retained. A multicenter, randomized, comparative effectiveness trial
was conducted to evaluate the effects of MSAT in aLBP with severe disability. A total of 58 aLBP patients
with severe functional disability (deﬁned per Oswestry Disability Index [ODI]P60%) were recruited and
assigned randomly to receive 1 session of either conventional diclofenac injection (n = 29) or MSAT
(n = 29). The primary outcome measured improvement in LBP using the 10-point numerical rating scale
of LBP, and the secondary outcome assessed disability using the Oswestry Disability Index at 30 minutes
and at 2, 4, and 24 weeks after treatment. Analyses were by intention to treat. The numerical rating scale
of the MSAT group decreased 3.12 (95% conﬁdence interval = 2.26, 3.98; P < .0001) more than that of the
injection group and the Oswestry Disability Index of the MSAT group decreased 32.95% (95% conﬁdence
interval = 26.88, 39.03; P < .0001) more than that of the injection group, respectively. The difference
between the 2 groups maintained statistical signiﬁcance at 2 and 4 weeks after treatment. These results
suggest that MSAT has positive effects on immediate pain relief and the functional recovery of aLBP
patients with severe disability.
 2013 International Association for the Study of Pain. Published by Elsevier B.V.
Open access under CC BY-NC-ND license. 1. Introduction
Although the natural history of back pain has been considered
favorable, with most cases of acute low back pain (aLBP) resolving
within weeks [34], a recent systematic review of the prognosis of
aLBP showed that this view of spontaneous healing is inaccurate.
Pain and disability are typically ongoing, and recurrences are com-
mon [5]. Up to 70% of patients who initially improve experience re-
peated ﬂuctuating pain episodes [26]. It was reported that back
pain patients classiﬁed as dysfunctional have more pain-speciﬁc
fear and avoidance. This disposition may be a factor in the transi-
tion from acute to chronic LBP [1]. Thus, effective treatments fortudy of Pain. Published by Elsevie
Korean Medicine, 635, Sinsa-
. Tel.: +82 2 3218 2188; fax:aLBP patients are needed to prevent the persistence of pain and
disability beyond the acute phase.
Recent systematic reviews of randomized clinical trials have
concluded that various types of nonsteroidal anti-inﬂammatory
drugs (NSAIDs) are effective for short-term symptomatic relief in
the early management of aLBP [19,38]. In the Cochrane review
on the role of NSAIDs, the effectiveness of NSAIDs was shown to
be more signiﬁcant than placebo in relieving aLBP [38]. Although
oral NSAIDs are widely used as a drug of ﬁrst choice for low back
pain, because of slow onset of action and modest analgesic po-
tency, the effects are rather limited in acute cases. Hence, in severe
cases of aLBP, parenteral administration of NSAIDs is preferred for
its rapid onset of action and strong analgesic properties
[4,25,30,37]. Diclofenac is the most commonly prescribed NSAID
and its efﬁcacy for relieving aLBP is well established [3,22], making
it the standard NSAID in treatment of such particular indications
[22,43]. In a randomized trial reported by Babej-Dölle et al., 2r B.V. Open access under CC BY-NC-ND license. 
J.-S. Shin et al. / PAIN

154 (2013) 1030–1037 1031groups of 82 patients with aLBP were each intramuscularly admin-
istered 3 ml of diclofenac-sodium (75 g) or 5 mL of isotonic saline
as a placebo. When the pooled effect size for the decrease in visual
analogue scale (VAS) of low back pain was estimated at 30 minutes
after baseline, the standardized mean difference (SMD) of diclofe-
nac compared to placebo was 0.38 [2].
Acupuncture has been extensively used to treat back pain, but
there has been continued controversy about its efﬁcacy. A system-
atic review concluded that acupuncture was found to be effective
for pain relief and functional recovery in chronic LBP in the short
term but not for aLBP [11]. Even LBP treatment guidelines recom-
mend acupuncture only for chronic back pain [6,37]. Motion style
acupuncture treatment (MSAT) is a relatively novel acupuncture
method that has been recently used increasingly often in South
Korea [18]. It is similar to traditional acupuncture in that needles
are inserted at speciﬁc acupuncture points, but is unique in that
it requires passive or active movement of the patient’s body while
acupuncture needles are retained.
To our knowledge, there are no previous trials that have studied
the effect of a treatment modality that combines acupuncture with
exercise in a manner comparable to MSAT for aLBP patients, nor
are there alternative clinical treatment guidelines for aLBP patients
who are unable to adhere to the general ‘‘remain active’’ recom-
mendations because of pain. This study was designed to examine
the effects of MSAT on aLBP patients with severe disabilities.2. Methods
2.1. Study design
This study was a multicenter, randomized, conventional diclofe-
nac injection–controlled, assessor-blinded, 2–parallel arm clinical
trial. It was conducted from April 2011 to April 2012, and patients
were recruited from April 2011 to October 2011. The patients were
randomly allocated to either MSAT group or active control group in
a ratio of 1:1. The experimental group received 1 session of MSAT,
and the active control group received 1 intramuscular injection of
NSAIDs. We observed the outcome variables 5 times: before treat-
ment, and 30 minutes and 2, 4, and 24 weeks after treatment.
This study protocol received approval from the Institutional Re-
view Boards of Jaseng Hospital of Korean Medicine, and was regis-
tered at ClinicalTrial.gov (NCT01315561). A full description of the
protocol was previously published [33]. Participants were not of-
fered economic incentives, but the treatment was free of charge
as compensation for participation. We did not restrict the patients’
option of treatment during the follow-up period. The study is re-
ported according to the Consolidated Standards of Reporting Trials
(CONSORT) [10] and STRICTA [21] guidelines.
2.2. Participants
The participants included in this study were recruited from 2
hospitals: Jaseng Hospitals of Korean Medicine located in Seoul
and Bucheon. Study researchers screened the eligibility of aLBP pa-
tients experiencing discomfort walking and requiring such assis-
tance as wheelchairs or stretchers. If eligible, all patients
underwent plain radiography and magnetic resonance imaging
(MRI) of the lumbar spine. Eligible participants were those be-
tween 20 and 60 years with aLBP of <4 weeks’ duration, with or
without radiating pain to the limb with an Oswestry Disability In-
dex (ODI) valueP60% as an indicator of severe disability. Exclusion
criteria were as follows: serious disease that could cause LBP (eg,
cancer, vertebral fracture, spinal infection); chronic disease that
could interfere with the effect of the treatment or the interpreta-
tion of treatment results (eg, cardiovascular disease, diabetic neu-ropathy, ﬁbromyalgia); progressive neurological deﬁcit or severe
neurological symptoms; conditions inappropriate or unsafe for
acupuncture (eg, hemorrhagic disease, blood coagulation disor-
ders); current intake of corticosteroids, immunosuppressant drugs,
psychiatric medicine; experience of gastrointestinal side effects
after taking NSAIDs or current treatment for gastrointestinal dis-
ease; pregnancy; and reluctance to accept the treatment regimens
or examinations (eg, X-ray, MRI) of this study.
All eligible participants were given verbal and written informa-
tion about the study and the 2 treatment alternatives. Each partic-
ipant voluntarily signed an informed consent form before
participating in the study.
2.3. Sample size
The sample size was estimated using the mean difference in
numerical rating scale (NRS) for LBP between the experimental
and control groups. Based on previous pilot studies, we set the ef-
fect size (Cohen’s d) at 0.8. Although the difference between the 2
groups in their mean NRS change scores was 2.3, we conservatively
set it as 2. The standard deviation of change of the NRS scores
pooled from the 2 groups was calculated as 2.5. When a 2-tailed
test with a test power of 80% and signiﬁcance level of 5% was ap-
plied [20], the number required for each group was 26 subjects.
For a successful study, a total of 58 subjects, with a 10% dropout
rate factored in, were required. Interim analysis was not to be per-
formed, or patient recruitment to be discontinued, unless the prin-
cipal investigator decided that there was an unacceptable risk of
serious adverse events in the groups.
2.4. Study interventions
MSAT was conducted by Korean medicine doctors who had
>5 years of clinical experience. The doctors conducting MSAT were
required to complete 3 workshop sessions before participating in
the study, to ensure that MSAT was conducted in the standardized
form as stated in the protocol [33]. (For more information see addi-
tional ﬁles 1 and 2 of the protocol [33], which contain the origin
and a detailed explanation of MSAT.)
We brieﬂy introduced the method of MSAT as follows: Two
assistants stand on both sides of the patient with their arms
around the patient’s waist while gently holding 1 of the patient’s
hands. In this position, the practitioner inserts disposable acupunc-
ture needles (40 mm  0.25 mm; Dong-bang Acupuncture, Seong-
Nam, Korea) to a depth of 10 to 15 mm at the subject’s Pungbu
(GV16) and on both sides of Haenggan (LR2) and Gokji (LI11).
These acupuncture points were selected according to traditional
Chinese medicine theory (qi circulation) [12,27] and previous clin-
ical experience. The location of each acupuncture point was deter-
mined using guidelines published by the World Health
Organization Standard Acupuncture Point Locations in theWestern
Paciﬁc Region [41]. No speciﬁc manipulation was used in this pro-
cess, and ‘‘Deqi’’ sensation was not sought, but practitioners occa-
sionally manually stimulated the needle inserted in GV16. With
the needles still retained at the acupoints, the patient is asked to
walk with assistance. The more the subject’s walking ability im-
proves and the pain is alleviated, the less the amount of support
to be provided, and the assistants are asked, 1 by 1, to gradually
stop supporting the subject. When the patient gains the ability to
walk without any support, all the needles are removed and the pa-
tient is asked to continue walking for another 1 to 2 minutes. The
practitioner also provided verbal encouragement to the patient, as
needed, to relieve the patient’s apprehension and fear of move-
ment. The average procedure takes up to about 20 minutes per pa-
tient. Video supplements of the MSAT procedure are available
(http://msat.jaseng.net/). In the control group, subjects received
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Pharmaceutical, SeongNam, Korea) in the gluteal region. Both
groups were informed of the favorable prognosis of aLBP and were
advised to remain active, if possible, within the range of nonaggra-
vation of pre-existing symptoms.
2.5. Outcome measurements
Assessing doctors were blinded to group assignment and did not
participate in the acupuncture treatment. Sex, age, height, weight,
blood pressure, and medical history were included in the baseline
demographic assessment. The initial evaluation of primary and sec-
ondary endpoints was carried out at baseline and 30 minutes after
baseline because, based on the investigators’ previous observations,
we know that the pain relief and improvement in motion due to
MSATappears immediately after treatment, and themaximumplas-
ma concentration for diclofenac occurs approximately 10 to 20 min-
utes after intramuscular injection [29]. Thus, 30 minutes after
baseline was the primary time point. We also performed additional
follow-upevaluations at 2, 4, and 24 weeks. Also, at the 24-week fol-
low-up, we checked as to whether any patients had received inpa-
tient treatment or surgical procedures at other institutions in
association with the current aLBP incidence, and, if so, the length
of their hospitalization. Radiology specialists who were blinded to
group allocation assessed the lumbar X-rays and MRIs. The lumbar
MRI readings were categorized into 4 groups: no protrusion or
extrusion; protrusion with no extrusion; extrusion; and both pro-
trusion and extrusion in the lumbar discs. The primary outcome re-
ferred to the intensity of aLBP evaluated through NRS by the trained
assessor. Although the NRS is a subjective evaluation indicator, it is
widely used because of its simplicity. Using the NRS, the patient
chooses 1 number, ranging from 0 to 10, that best expresses their
current level of pain (0 being no pain, and 10 being the most excru-
ciating pain that the subject has ever experienced) [9,35]. As the
severity of pain can differ at rest and during activity, patients were
asked to indicate the intensity of pain that they felt as they tried to
move. The NRS for aLBP was assessed at baseline and at 30 minutes
after and 2, 4, and 24 weeks after treatment. Secondary result out-
comes included functional status using the accredited Korean ver-
sion of the ODI questionnaire [8]. It was recorded at baseline and
at 30 minutes after and 2, 4, and 24 weeks after treatment. We also
evaluated the patient global impression of change (PGIC) [9], which
enables patients to subjectively assess their improvement at
30 minutes and at 24 weeks after treatment. We also checked the
patients’ lumbar range of motion (ROM) and degree of straight leg
raising (SLR) to determine the change in movement between base-
line and 30 minutes after treatment. The measurement of ROM is
reliable (r = 0.94) and valid (r = 0.97) [32] but not very responsive
(effect size = 0.1–0.6) [15]. Also, the measurement of SLR is reliable
(intraclass correlation coefﬁcient = 0.95) [7], the sensitivity is 0.8
(72%–97%), and the speciﬁcity is 0.4 (11%–66%) [28], but it is not very
responsive (effect size = 0.2). As the responsiveness of ROM and SLR
measurement is not high, we decided to use it only as a secondary
outcome measure. When assessing the NRS for leg pain, we asked
the patients to indicate the intensity of pain that they felt in each
leg as they tried to move, and we recorded the NRS of the leg with
the higher score at baseline. The NRS for leg pain was checked at
baseline and at 30 minutes after and 2, 4, and 24 weeks after treat-
ment. Any adverse events were monitored and reported as second-
ary outcomes. No changes were made to the prespeciﬁed trial
outcome measures [33] after the trial commenced.
2.6. Randomization and allocation concealment
Randomization was conducted by a statistics specialist who had
no contact with the participants. Random numbers with block ran-domization were generated using the SAS version 9.1.3 statistical
package (SAS Institute, Cary, NC), and a block size of 6 was used
to allocate the 2 groups (1:1 ratio). A statistics specialist generated
the random allocation sequence. Korean medicine doctors who had
received prior training enrolled participants and conducted the
data collection sessions, and the randomized numbers were kept
in sealed envelopes by a researcher who had no direct contact with
the study participants. Random allocation was conducted by open-
ing an envelope as the researcher was informed of a participant’s
registration at each clinical trial center. Before the randomization
allocation, participants were informed that they would be assigned
to 1 of the 2 groups. Random allocation was performed if a partic-
ipant was eligible and had signed the informed consent form. The
subject identiﬁcation codes were recorded on the case report forms
(CRFs) and randomization table.
2.7. Blinding
Assessor-blinding was achieved by blinding the assessor per-
forming outcome assessment and CRF data entry to the random
allocation, as blinding of participants or practitioners was impossi-
ble because of the nature of the treatment. Statistical analysis was
performed by an independent statistician who was blinded to the
identiﬁcation of each treatment group.
2.8. Statistical analysis
Continuous variable data was expressed as mean ± standard
deviation (SD) and compared using the independent t test. Cate-
gorical variables were expressed as numbers or percentages and
compared using the v2 test or Fisher exact test, as appropriate.
Moreover, if the normality assumption was violated, the Mann–
Whitney U test would be used. For the comparison of NRS, ODI,
ROM, and SLR between the 2 groups, an independent t test was
used, followed by calculation of effect size (Cohen’s d) with a 95%
conﬁdence interval. The results were considered to be statistically
signiﬁcant when P was <0.05. All adverse events reported during
the study were included on the CRFs, and the incidence of adverse
events was calculated. The percentage of subjects with adverse
events, the percentage that received inpatient care in association
with the current aLBP incidence, and the length of hospital stay
in each group was calculated and compared using the v2 test or
Fisher exact test. By the principle of intention-to-treat analysis,
the last observed value (non-missing value) was used to ﬁll in
missing values at a later point in the study. All statistical analyses
were performed using SAS version 9.1.3 software.3. Results
In all, 93 consecutive patients with aLBP were screened, and of
these patients 58 were enrolled (Fig. 1). A total of 29 were random-
ized to each group, and all patients completed treatment with no
drop-outs or adverse events. All 58 patients were evaluated at
the 30-minute follow-up. The patients were re-evaluated at 2, 4,
and 24 weeks after treatment by telephone interview. The fol-
low-up rate was different for each evaluation. A total of 24 patients
in the MSAT group and 27 in the injection group answered the en-
tire follow-up questionnaire at 24 weeks. However, we were able
to investigate the length of hospital stays, number of hospital vis-
its, or surgery in greater numbers of patients (Table 3).
3.1. Demographic data
There were no statistically signiﬁcant differences between the 2
groups in the baseline demographic and clinical features (Table 1).
Fig. 1. Recruitment and follow-up of study participants.
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pain at baseline visit regardless of prior LBP incidents. There was
no signiﬁcant difference between the 2 groups in the mean NRS
of low back pain and leg pain, ODI, ROM, and SLR at baseline.
The NRS of low back pain, which was the primary outcome mea-
sure, of the MSAT group was superior to that of the injection group
at 30 minutes. This difference was maintained at 2 and 4 weeks,
but the difference gradually decreased, with no signiﬁcant differ-
ence at 24 weeks. Whereas the NRS of leg pain in the MSAT group
showed a signiﬁcant decrease at 30 minutes after treatment, the
injection group did not. Both groups presented with a signiﬁcant
decrease at 2 and 4 weeks, and at 24 weeks the injection group
showed a greater reduction in pain. There was a signiﬁcant de-
crease in the ODI score of the MSAT group at 30 minutes after
treatment, whereas there was not in the injection group. The MSAT
group showed a more signiﬁcant difference than the injection
group at 30 minutes and at 2 and 4 weeks, but not at 24 weeks.
Furthermore, the MSAT group showed a signiﬁcant difference in
SLR at 30 minutes (Table 2).
In PGIC, the MSAT group showed a higher level of satisfaction
(1.90 ± 0.67) than the injection group (3.62 ± 0.62) (P < .0001) at
30 minutes. However, at the 24-week follow-up there was no sig-
niﬁcant difference between the 2 groups. Only 3 patients in theMSAT group and none in the injection group could be assessed
for the ROM of lumbar ﬂexion and extension at baseline, and the
rest could not because of patients’ refusal of measurement due to
severe pain and/or disability. The lumbar ROM of 27 patients in
the MSAT group could be measured, and the mean lumbar ﬂexion
and extension measurement were 22.07 ± 25.48 and 7.41 ± 7.02,
respectively. The lumbar ROM could be measured in only 1 patient
in the injection group, and the rest refused.
3.2. Post hoc outcome measures
All participants consulted with different physicians from those
who conducted previous treatment regarding inpatient/outpatient
treatment plans after the initial MSAT or injection treatment. Inpa-
tients received an integrative package (consisting of herbal medi-
cine, Chuna manipulation, bee venom pharmaco-acupuncture,
and acupuncture) [24] an average of 5 sessions a week, and outpa-
tients once or twice a week (Table 3). Although the physicians who
were not involved in data collection or group allocation were not
informed of the purpose of this trial, they were still not blinded
to the patients’ previous treatments.
We investigated whether the participants received inpatient
care in association with the current aLBP incidence, and found that
Table 1
Demographic and clinical features of the participants at baseline.
Variables Total N (%) Group P value
MSAT (n = 29) Injection (n = 29)
Sex
Male 34 (59) 19 (66) 15 (52) .2862
Female 24 (41) 10 (34) 14 (48)
Age, y (mean ± SD) 38.31 ± 7.97 37.93 ± 7.37 38.69 ± 8.64 .7204
BMI, kg/m2 (mean ± SD) 23.91 ± 3.64 24.18 ± 3.37 23.63 ± 3.93 .5729
Duration, days (mean ± SD) 1.76 ± 1.97 1.41 ± 1.45 2.10 ± 235 .1854
MRI ﬁndings
Bulging 4 (7) 3 (10) 1 (3) .3638
Protrusion 33 (57) 18 (62) 15 (52)
Extrusion 8 (14) 2 (7) 6 (21)
Protrusion and extrusion 13 (22) 6 (21) 7 (24)
BMI, body mass index; MRI, magnetic resonance imaging.
Data are n (%) or mean ± SD. Continuous variables were calculated by 2-sample t test, and categorical variables were calculated by the v2 test.
Table 2
Difference in primary and secondary results of motion style acupuncture treatment (MSAT) group and nonsteroidal anti-inﬂammatory drug injection group between each
evaluation and baseline (change from baseline to follow-up time point).
Variable Baseline Change from baseline to follow-up time point
30 Minutes 2 Weeks 4 Weeks 24 Weeks
NRS- LBP
MSAT 8.33 ± 1.91 3.83 ± 2.05* 5.83 ± 2.61* 6.41 ± 2.45* 6.64 ± 2.47*
Injection 8.12 ± 1.63 0.71 ± 1.06* 4.17 ± 3.05* 4.91 ± 2.94* 6.84 ± 1.9*
Difference (95% CI) 3.12 (2.26, 3.98) 1.66 (0.16, 3.15) 1.5 (0.08, 2.92) 0.21 (1.37, 0.95)
P value .6598 <.0001 .0305 .0393 .7221
NRS, leg pain
MSAT 2.31 ± 3 1.22 ± 1.88* 1.57 ± 2.7* 1.59 ± 2.78* 1.64 ± 2.46*
Injection 4.1 ± 4.11 0.26 ± 0.7 1.83 ± 2.66* 2.33 ± 3.06* 3.48 ± 3.62*
Difference (95% CI) 0.97 (0.22, 1.71) 0.26 (1.67, 1.15) 0.74 (2.28, 0.8) 1.85 (3.47, 0.22)
P value .0628 .0137 .7149 .3386 .0276
ODI
MSAT 85.72 ± 10.46 33.37 ± 14.91* 56.41 ± 24.86* 62.72 ± 21.88* 73.23 ± 20.24*
Injection 88.34 ± 7.71 0.41 ± 6.64 36.34 ± 29.1* 45.84 ± 29.58* 80.83 ± 13.58*
Difference (95% CI) 32.95 (26.88, 39.03) 20.07 (5.83, 34.31) 16.88 (3.19, 30.57) 7.6 (16.67, 1.47)
P value .2820 <.0001 .0066 .0166 .0995
SLR
MSAT 41.9 ± 26.61 15.00 ± 20.27
Injection 37.76 ± 25.79 1.38 ± 14.75
Difference (95% CI) 13.62 (4.3, 22.95)
P value .5500 .005
Data are mean ± standard deviation. Outcome results at baseline and post treatment at 30 minutes and at 2, 4, 24 weeks were compared between the 2 groups with
independent-sample t test.
NRS, numerical rating scale; ODI, Oswestry Disability Index; SLR, straight leg raising; CI, conﬁdence interval.
* <.005
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than the injection group. Although the length of hospital stay in
the MSAT group was shorter than the injection group, the differ-
ence did not reach statistical signiﬁcance. Although we could not
conﬁrm the surgical status of 6 patients at 24 weeks, 1 patient in
the injection group who completed the 24-week follow-up re-
ported having received surgery because of the current LBP.
4. Discussion
Our study has shown that MSAT was more effective for pain and
function in aLBP patients with severe disability in the short term
and up to 4 weeks than was conventional NSAID injection. These
results suggest that MSAT has superior effects on pain and func-
tional status as shown by the NRS of LBP, NRS of leg pain, ODI
scores, lumbar ROM, and range of SLR over those of the NSAID
injection control.Statistically signiﬁcant results may differ from clinically signif-
icant results and it was reported by Ostelo and de Vet that a reduc-
tion in NRS of P3.5 and improvement in ODI scores of P10 are
clinically signiﬁcant in LBP patients [23]. In the MSAT group, the
NRS of LBP decreased 3.83 ± 2.05, and the ODI 33.37 ± 14.91, which
are clinically signiﬁcant levels of pain reduction and functional
recovery. These results were also reﬂected in the admittance rate
of patients. Whereas 93% of the NSAID group patients opted for
hospitalization because of little improvement in functional disabil-
ity (0.41 ± 6.64), 66% of the MSAT group chose to receive hospital-
ization with greater improvement in function (33.37 ± 14.91). The
difference in the admittance rate of patients between groups was
statistically signiﬁcant. Although the duration of hospital stay
was shorter in the MSAT group, the statistics did not reach statis-
tical signiﬁcance.
The main shortcoming of this study is that we were unable to
blind the patient and physician simultaneously. The divergence be-
Table 3
Medical service use and period during the 24-week follow-up (in association with the current aLBP incidence).
Total MSAT
(n = 29)
Injection
(n = 29)
P value
Type
Inpatient, n (%) 46 19 (66) 27 (93) .021
Outpatient, n (%) 12 10 (34) 2 (7)
Hospital stay, n (days, mean ± SD) 46 (15.74 ± 10.95) 19 (12.58 ± 8.24) 27 (17.96 ± 12.17) .101
Surgery*
No, n (%) 51 (98) 24 (100) 27 (96) 1.0000
Yes, n (%) 1 (2) 0 1 (4)
Continuous variables were calculated by 2-sample t test, and categorical variables were calculated by v2 test.
* Variable had 6 missing values.
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the patient and physician both. Although the assessors were
blinded, whereas the majority of patients in the MSAT group re-
gained mobility after treatment, the patients in the injection group
still tended to show difﬁculty in movement, which made the group
allocation of the patient rather obvious to physicians familiar with
MSAT through clinical experience or the previous pilot study.
Therefore, to increase objectivity, the questionnaire measurements
such as NRS, ODI, and PGIC, which can be made on paper, were
fully explained to the patients at baseline, and then identical forms
were used at baseline and the 30 minute follow-up. Also, in the
telephone follow-ups, assessors blinded to previous treatment con-
ducted the questionnaires. However, the fact that the successful-
ness of the blinding attempts was not assessed could be a major
limitation of this study.
Because the setting was a Korean medicine hospital, and be-
cause patients visit for the speciﬁc purpose of receiving Korean
medicine, there is a fair possibility that patients would be more
favorably inclined toward acupuncture, and that this propensity
may have affected the results. Also, whereas patients in the MSAT
group received treatment and support from the practitioners for
20 minutes, patients in the NSAID group had only a brief encounter
with the practitioners at time of injection, which may have inﬂu-
enced the overall level of psychological stability and satisfaction.
The fact that the patients’ expectations, pretreatment prefer-
ences, or credibility questionnaires were not assessed could be a
further limitation of this study, especially in light of previous re-
search results that have reported the large placebo effect of acu-
puncture [11]. Nevertheless, the placebo effect can also be
considered an active part of the total therapeutic effect. Even if
the placebo effect of MSAT is greater than other conventional treat-
ments, if the total therapeutic effects of MSAT are superior, MSAT
could still be considered a clinically advantageous and valid treat-
ment. Furthermore, the more objective ‘‘hard’’ outcome measures,
such as hospitalization rates and length of hospital stay, reinforce
the argument that the remarkable therapeutic effects of MSAT
measured with the more subjective outcome measures such as
NRS or ODI, which are more prone to being affected by placebo ef-
fects, are an intrinsic attribute. These exceptional results could not
be explained in their entirety simply as a placebo effect.
Another limitation of this study is related to the time-based ef-
fect of diclofenac. Although it is known that the maximum plasma
concentration of diclofenac is 10 to 20 minutes after intramuscular
injection and that the effectiveness is maintained from 30 minutes
to more than 4 hours [17,29], whether 30 minutes after treatment
is the most appropriate time frame to observe the reduction in pain
for both interventions is open to debate. In both groups, we did not
restrict the selection of treatment after the initial treatment ses-
sion, because of ethical reasons, which implies that the results after
the ﬁrst follow-up at 30 minutes are not clean and therefore are
difﬁcult to generalize.A systematic review analyzed 35 RCTs on LBP covering 2861 pa-
tients from 1966 to 2003, but reported insufﬁcient evidence to
make any recommendations about acupuncture or dry-needling
for aLBP. Of the analyzed RCTs, 1 clinical trial by Wu [42] et al. in
150 patients with aLBP stands out as the only trial combining acu-
puncture with movement. After applying acupuncture at Extra 29
(EX-UE7), which is an acupuncture point located on the hand, a
strong Deqi sensation was obtained by combining acupuncture
with lumbar spine movement until symptoms were relieved. The
results showed that this manual technique was less effective than
traditional acupuncture at acupoint SI 3. However, the treatment
method was different from MSAT, and this study also has the lim-
itation of low methodological quality, with a score of 3 out of 10 in
the Methodological Quality Assessment by the review authors. The
other trials analyzed used meridian or trigger point stimulation
techniques in acupuncture or dry needling.
Recently, more studies are focusing on the practicality of acu-
puncture for aLBP. One recent rigorous RCT by Vas et al. allocated
275 acupuncture-naive patients with nonspeciﬁc aLBP into 4
groups. One group received conventional treatment only (patients
were advised and were prescribed paracetamol or NSAIDs in accor-
dance with clinical guidelines), and the other 3 groups received
acupuncture, sham acupuncture, and placebo acupuncture, respec-
tively, in addition to conventional treatment. The 3 groups receiv-
ing acupuncture reported greater reduction in disability scores and
intake of conventional drugs than did the conventional treatment
group [39].
The mechanisms underlying the immediate effects in pain
reduction and steady recovery of function in MSAT are, as yet,
unclear. However, based on previous research, it may be sug-
gested that acupuncture analgesia and a cognitive shift in percep-
tion of pain are involved. The strong stimulation of distal
acupuncture points in MSAT may enhance the effects of pain re-
lief by triggering ‘‘diffuse noxious inhibitory controls’’ and
increasing secretion of endorphins by stimulating internal activ-
ity of the central nervous system [40]. If patients feel less pain
and gain more mobility with encouragement and MSAT treat-
ment, the treatment could create a positive cycle leading to
heightened therapeutic effects. Patients with severe LBP may
have a negative interpretation of pain, which in turn may induce
physiological, cognitive, and fear avoidance responses [31,36].
Fear and negative cognition toward pain may result in evasion
of movement that leads to disability and pain, forming a negative
pain cycle [1,13,34]. These unwanted consequences could possi-
bly be averted with MSAT, thus enabling patients to follow the
general advice of avoiding bed rest and remaining active as sug-
gested in guidelines for aLBP [14,16].
As the participants in our trial were screened from among pa-
tients experiencing difﬁculty walking or those dependent on
wheelchairs or stretchers because of severe aLBP without severe
neurological symptoms or deﬁcit, we cautiously but hopefully
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nonspeciﬁc aLBP patients in typical clinical settings also. All of the
participants’ lumbar MRI ﬁndings revealed disc protrusions and/or
disc extrusions, with an exception of 4 (6.90%) participants.
According to a systematic review, the false-positive detection of
lumbar disc herniation by MRI in LBP or sciatica patients is esti-
mated to be high at 23% (95% conﬁdence interval = 12%–39%), but
the MRI readings of the aLBP patients that participated in our study
demonstrated a very high sensitivity. Therefore MSAT has applica-
tions not only for nonspeciﬁc LBP patients but also for herniated
disc patients with aLBP and/or leg pain. Although Korean and Asian
patients typically have more exposure to and less aversion to acu-
puncture, the participants in our trial, except for 1 patient, were
unaccustomed to the concept of active movement during acupunc-
ture. The fact that no patients from the MSAT group dropped out
during the treatment session can be taken as an indication that
movement during acupuncture at certain points does not act as
an aggravating factor or cause signiﬁcant adverse effects and/or
exacerbation of fear.
4.1. Conclusion
It is concluded that this study showed highly positive effects on
pain and function through the collaborative treatment of acupunc-
ture and motion style in aLBP patients. The results make a contri-
bution to the prior knowledge of the effects of acupuncture on
aLBP. We expect that additional studies comparing MSAT with tra-
ditional acupuncture and investigations of post-MSAT MRI follow-
up results of patients experiencing severe disability because of
acute disc herniation will shed more light on this area.
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